[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619891":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":30,"responsibleParty":47,"collaborators":11,"id":51,"slug":11,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":11,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":11,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":75,"whyStopped":11,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"University of Copenhagen","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Alanine infusion","EXPERIMENTAL",null,[13],"Other: alanine",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":11},"alanine","A three-hour intravenous infusion with alanine with increasing infusion rate (from 1.4 μmol\u002Fkg\u002Fmin and to 28 μmol\u002Fkg\u002Fmin)",[9],[20],{"name":21,"affiliation":22,"role":23},"Nicolai Jacob Wewer Albrechtsen, MD PhD","Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":11,"email":29},"Elvar Már Sturlaugsson Jóhönnuson, Stud. Med.","CONTACT","21205944 Ext. 0045","elvar.mar.sturlaugsson@regionh.dk",[31],{"facility":32,"status":11,"city":33,"state":11,"zip":11,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg","Copenhagen","Denmark","DK",{"type":37,"coordinates":38},"Point",[39,40],12.56553,55.67594,{"lat":40,"lon":39},[43],{"name":44,"role":27,"phone":45,"phoneExt":11,"email":46},"Sophie BB Johnsen, MD","004521205944","sophie.betty.brock.johnsen.01@regionh.dk",{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Nicolai Jacob Wewer Albrechtsen","Principal Investigator","100619891",false,"NCT07350512","Investigating the Acute Effects of Increasing Alanine Exposure in Healthy Participants","Investigating the Effect of Glucagon on Cognitive Function and Cerebral Glucose Metabolism in Humans: A Pilot Study","Inclusion Criteria:\n\n* Capable of understanding the participant information and signing the consent form\n* Between 25 and 70 years of age at the time of screening\n* Body mass index (BMI) ≤ 25 kg\u002Fm2 at the time of screening\n\nExclusion Criteria:\n\n* Enrolment in other research projects that might interfere with the study\n* Diabetes diagnosis (type 1 and 2)\n* Pregnancy or breastfeeding\n* Use of medications which, in the opinion of the investigator, may jeopardise participant's safety or compliance with the protocol\n* Impaired liver function defined as either alanine aminotransferase (ALAT) and\u002For aspartate aminotransferase (ASAT) ≥ 2 times normal values\n* Kidney disease defined as serum creatinine levels ≥ 126 μmol\u002FL for male and ≥ 111 μmol\u002FL for female\n* Inadequately treated blood pressure at screening defined as repeated resting blood pressure outside the range 90-150 mmHg for systolic and 50-100 mmHg for diastolic\n* Active or recent malignant disease\n* Current or history of severe alcohol use or drug\u002Fchemical abuse as per investigator's judgement\n* Any chronic disorders or severe diseases which, in the opinion of the investigator, might jeopardise participant's safety or compliance with the protocol",true,"ALL","25 Years","70 Years",{"count":62,"type":63},15,"ESTIMATED","INTERVENTIONAL",[66],"NA","In this study the investigators will investigate the acute effects of increasing alanine exposure on metabolic parameters in healthy participants.\n\nParticipants will participate in one study day. After initial baseline blood samples, a three-hour intravenous infusion with glucagon will be initiated. The infusion rate will be increased every 30 minutes.",[69,70],"Glucose Metabolism","Glucagon",[72,73,74],"Alanine","glucagon","glucose metabolism","NOT_YET_RECRUITING","2026-01-09",{"date":78,"type":79},"2026-01-20","ACTUAL",{"date":78,"type":63},{"date":82,"type":63},"2027-01-20",{"name":49,"class":6},1]